InflaRx, which is developing new therapeutics to treat acute and terminal inflammation, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Jena, Germany-based company was founded in 2007 and plans to list on the Nasdaq under the symbol IFRX. InflaRx filed confidentially on June 23, 2017. J.P. Morgan, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
